EXHIBIT 16.1

April 22, 2016

U.S. Securities and Exchange Commission

Office of the Chief Accountant

100 F Street, N.E.

Washington, DC 20549

Commissioners:

We have read Item 4.01 of Form 8-K, dated April 22, 2016, of Cerebain Biotech Corp. and agree with the statements concerning our Firm contained therein.

Very truly yours,

/s/ Hartley Moore Accountancy Corporation                                 

Hartley Moore Accountancy Corporation